Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA, Penn get personal

This article was originally published in The Tan Sheet

Executive Summary

Following FDA's Sept. 12 health information advisory regarding melamine-contaminated infant formula from China, the agency says Sept. 23 "there is no known threat of contamination in infant formula manufactured by companies that have met the requirements to sell such products in the United States." While state and local officials collaborating with the agency have not found Chinese formula on store shelves in large Asian enclaves in the U.S., FDA says it is taking "proactive measures" to sample and test other imported milk-derived ingredients and finished food products for Chinese milk proteins (2"The Tan Sheet" Sept. 15, 2008, In Brief)

You may also be interested in...



FDA warns on China formula

Milk-based infant formula manufactured in China may be contaminated with melamine, which raises the protein profile of dairy products and may have contributed to reports of kidney stones in Chinese infants, FDA says Sept. 12. The agency says companies approved for marketing milk-based formula in the U.S. are not importing materials from China, though officials are investigating whether Chinese infant formula is being sold in Asian specialty markets inside the U.S. In its same-day health information advisory, FDA requests the help of states in removing Chinese infant formula products from store shelves. In April 2007, melamine-tainted Chinese pet food caused FDA to issue an import alert on vegetable proteins from China (1"The Tan Sheet" May 21, 2007, p. 6)

Novartis And The Medicines Company: Five Things To Worry About

The $9.7bn acquisition hinges on the small interfering RNA inclisiran, but an ongoing cardiovascular outcomes trial, manufacturing hurdles, and reimbursement challenges provide subjects for concern.

QUOTED. 12 December 2019. Scott Whitaker

US congressional leaders and medtech industry advocacy group AdvaMed are giving their full-throated endorsement to a US-Mexico-Canada (USMCA) trade agreement announced by the US Trade Representative's Office on 10 December. See what AdvaMed's president and CEO, Scott Whitaker, said about it in a statement here.

Topics

UsernamePublicRestriction

Register

PS102142

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel